Before being identified as a NLRP3 inhibitor, Tranilast showed beneficial effects in cardiac fibrosis and remodeling in several animal models of hypertension, diabetic cardiomyopathy and myocardial infarction [113,114,115]. Here, NLRP3 is linked to myocardial infarction.